Y Intercept Hong Kong Ltd Invests $1.97 Million in Inspire Medical Systems, Inc. $INSP

Y Intercept Hong Kong Ltd acquired a new position in Inspire Medical Systems, Inc. (NYSE:INSP) during the second quarter, according to its most recent filing with the SEC. The firm acquired 15,166 shares of the company’s stock, valued at approximately $1,968,000. Y Intercept Hong Kong Ltd owned about 0.05% of Inspire Medical Systems as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the business. Nisa Investment Advisors LLC grew its position in shares of Inspire Medical Systems by 783.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,368 shares of the company’s stock worth $307,000 after buying an additional 2,100 shares during the last quarter. State of New Jersey Common Pension Fund D grew its position in shares of Inspire Medical Systems by 20.8% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 12,905 shares of the company’s stock worth $1,675,000 after buying an additional 2,223 shares during the last quarter. AlphaQuest LLC grew its position in shares of Inspire Medical Systems by 178.3% in the 2nd quarter. AlphaQuest LLC now owns 2,861 shares of the company’s stock worth $371,000 after buying an additional 1,833 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Inspire Medical Systems in the 2nd quarter worth approximately $921,000. Finally, William Blair Investment Management LLC grew its position in shares of Inspire Medical Systems by 11.0% in the 2nd quarter. William Blair Investment Management LLC now owns 769,169 shares of the company’s stock worth $99,815,000 after buying an additional 76,251 shares during the last quarter. 94.91% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Inspire Medical Systems

In other news, CFO Richard Buchholz sold 11,000 shares of the business’s stock in a transaction on Friday, August 29th. The stock was sold at an average price of $93.39, for a total value of $1,027,290.00. Following the completion of the transaction, the chief financial officer owned 44,867 shares in the company, valued at $4,190,129.13. The trade was a 19.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.10% of the stock is owned by corporate insiders.

Inspire Medical Systems Trading Down 1.5%

Inspire Medical Systems stock opened at $71.97 on Friday. The business’s fifty day simple moving average is $80.76 and its two-hundred day simple moving average is $113.89. Inspire Medical Systems, Inc. has a 12 month low of $70.77 and a 12 month high of $216.01. The company has a market capitalization of $2.13 billion, a price-to-earnings ratio of 41.60, a price-to-earnings-growth ratio of 2.26 and a beta of 1.16.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, August 4th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.22 by $0.23. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%.The business had revenue of $217.09 million for the quarter, compared to the consensus estimate of $214.50 million. During the same period in the previous year, the company posted $0.32 earnings per share. The company’s revenue for the quarter was up 10.8% compared to the same quarter last year. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. On average, equities research analysts predict that Inspire Medical Systems, Inc. will post 2.16 EPS for the current year.

Inspire Medical Systems declared that its board has authorized a stock buyback program on Monday, August 11th that allows the company to repurchase $200.00 million in shares. This repurchase authorization allows the company to buy up to 8.6% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on INSP shares. Wall Street Zen lowered Inspire Medical Systems from a “buy” rating to a “hold” rating in a research report on Saturday, July 26th. Lake Street Capital set a $150.00 price target on Inspire Medical Systems and gave the company a “buy” rating in a research report on Tuesday, August 5th. Wells Fargo & Company dropped their price target on Inspire Medical Systems from $174.00 to $101.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 5th. Royal Bank Of Canada restated an “outperform” rating and set a $150.00 price target on shares of Inspire Medical Systems in a research report on Friday, October 10th. Finally, JPMorgan Chase & Co. lowered Inspire Medical Systems from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $195.00 to $110.00 in a research report on Tuesday, August 5th. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $141.13.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.